Introduction & Objective: To explore the association between using an automated insulin delivery (AID) system and physical activity (PA) frequency among people with type 1 diabetes (T1D).
Methods: Cross-sectional study using the Canadian BETTER T1D registry. Inclusion criteria: T1D; aged ≥ 18 y/o; reported PA with a validated questionnaire (Canadian Community Health Survey). “PA” includes organized or unorganized sports, fitness or recreational PA lasting ≥ 10 consecutive minutes; “moderate to vigorous PA” is PA that makes participants sweat at least a little and breathe harder. Regression models (with and without adjustment for imbalanced variables - sex, age, T1D duration) were used to compare PA frequency among treatment options, with pairwise comparison between the AID group and each of the other groups.
Results: Among 1213 participants, the AID group and pump+continuous glucose monitoring (CGM) group had a similar frequency of PA and moderate to vigorous PA, but these levels were higher in the AID group than those of injections+CGM and no-CGM groups (Table).
Conclusion: In real-world settings, compared with injections+CGM or No-CGM, AID users within the BETTER T1D registry have a higher frequency of PA and moderate to vigorous PA. However, these frequencies are similar between AID and pump+CGM users.
Z. Wu: None. J.E. Yardley: Speaker's Bureau; Dexcom, Inc. Research Support; LifeScan Diabetes Institute. T. Chahal: None. C. Guédet: None. V. Messier: None. C. Grou: None. V. Boudreau: None. A. Brazeau: Other Relationship; Dexcom, Inc. Research Support; Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation (JDRF), Diabète québec, Fonds de recherche du Québec en Santé. R. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète.
Canadian Institutes of Health Research (JT1-157204) and Juvenile Diabetes Research Foundation (4-SRA-2018-651-Q-R)
